Beatriz Carvalho
Senior scientist
Research Interests
Make your next move.
Prepare your application
Review drafts before you send them.
Explore related searches
Articles (9)
Year:
2026
Year:
2025
Year:
2025
Up to 30% of colorectal cancers (CRCs) develop from sessile serrated lesions (SSLs). Within the serrated neoplasia pathway, at least two principally distinct oncogenetic routes exist generating microsatellite‐stable and microsatellite‐instable CRCs, respectively. Aberrant DNA methylation (DNAm) is found early in the serrated pathway and might play a role in both oncogenetic routes. We studied a cohort of 23 SSLs with a small focus (<10 mm) of dysplasia or cancer, 10 of which were MLH1 deficient and 13 MLH1 proficient. By comparing, for each SSL, the methylation status of (1) the region of dysplasia or cancer (SSL‐D), (2) the nondysplastic SSL (SSL), and (3) adjacent normal mucosa, differentially methylated probes (DMPs) and regions (DMRs) were assessed both genome‐wide as well as in a tumor‐suppressor gene‐focused approach. By comparing DNAm of MLH1‐deficient SSL‐Ds with their corresponding SSLs, we identified five DMRs, including those annotating for PRDM2 and, not unexpectedly, MLH1 . PRDM2 gene promotor methylation was associated with MLH1 expression status, as it was largely hypermethylated in MLH1‐deficient SSL‐Ds and hypomethylated in MLH1‐proficient SSL‐Ds. Significantly increased DNAm levels of PRDM2 and MLH1 , in particular at ‘critical’ MLH1 probe sites, were to some extent already visible in SSLs as compared to normal mucosa ( p = 0.02, p = 0.01, p < 0.0001, respectively). No DMRs, nor DMPs, were identified for SSLs destined to evolve into MLH1‐proficient SSL‐Ds. Our data indicate that, within both arms of the serrated CRC pathway, the majority of the epigenetic alterations are introduced early during SSL formation. Promoter hypermethylation of PRDM2 and MLH1 on the other hand specifically initiates in SSLs destined to transform into MLH1‐deficient CRCs suggesting that the fate of SSLs may not necessarily result from a stochastic process but possibly is already imprinted and predisposed.
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2023
Year:
2023
Collaborators (13)
Robert JC Steele
Research Professor
-
Gerrit Meijer
Professor of Oncologic Pathology
University Medical Center Groningen
Robert Bresalier
Professor
The University of Texas MD Anderson Cancer Center
Dimitrios Mathios
Assistant Professor
Washington University in St. Louis
Claus Lindbjerg Andersen
VIP, Professor
Aarhus University
Graeme Young
Flinders University
Evelien Dekker
Professor
Amsterdam University Medical Centers
Lydia GUITTET
Université de Caen Normandie
Ronny Drapkin
Franklin Payne Professor of Pathology in Obstetrics and Gynecology
University of Pennsylvania
Lana Meiqari
University of Amsterdam
Carel JM van Noesel
Amsterdam University Medical Centers
Beatrice Lauby-Secretan
Head, IARC Handbooks Programme
International Agency for Research on Cancer
Soufyan Lakbir
Utrecht University
Make your next move.
Prepare your application
Review drafts before you send them.